The disease specific analysis showed that there was a significant variability in the number of hyper- and hypomethylated probes, with IDH mutated AML showing the highest number of hypermethylated probes (Fig. 1a,b) compared to IDH mutant Astrocytoma (Fig. 1c) and Oligodendroglioma (Fig. 1d), suggesting that other factors such as concurrent driver mutations of IDH wild-type tumors or the tissue of origin play role in tumor type specific methylation changes. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).